ADC Therapeutics SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ADC Therapeutics SA
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.
- Large Molecule
- Other Names / Subsidiaries
- ADC Therapeutics Sarl
- ADC Therapeutics S.A.